Journal article
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer
Abstract
Uncertainty remains about the optimal anti-emetic regimen for control of delayed nausea and vomiting after adjuvant chemotherapy for breast cancer. Many patients receive dexamethasone but complain of insomnia, anxiety/agitation, and indigestion. The aim was to determine if patients receiving chemotherapy for breast cancer prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting, and to compare quality …
Authors
Vardy J; Pond G; Dodd A; Warr D; Seruga B; Clemons M; Bordeleau L; Goodwin P; Tannock IF
Journal
Breast Cancer Research and Treatment, Vol. 136, No. 1, pp. 143–151
Publisher
Springer Nature
Publication Date
November 2012
DOI
10.1007/s10549-012-2205-3
ISSN
0167-6806